13-hydroxy-9-11-octadecadienoic-acid and Carcinoma--Hepatocellular

13-hydroxy-9-11-octadecadienoic-acid has been researched along with Carcinoma--Hepatocellular* in 2 studies

Other Studies

2 other study(ies) available for 13-hydroxy-9-11-octadecadienoic-acid and Carcinoma--Hepatocellular

ArticleYear
Omega-6-derived oxylipin changes in serum of patients with hepatitis B virus-related liver diseases.
    Metabolomics : Official journal of the Metabolomic Society, 2018, 01-31, Volume: 14, Issue:3

    Chronic hepatitis B virus (HBV) infection is the main etiologic risk factor for hepatocellular carcinoma (HCC). Early studies indicated that the increase of omega-6-derived oxylipins may be involved in the pathogenesis of HBV-related HCC, yet their changes during the distinct clinical phases of chronic HBV infection remain unclear. To fill this gap, in this study we investigated the omega-6-derived oxylipin profiles in patients with three major clinical stages of chronic HBV infection (chronic hepatitis B, liver cirrhosis, and HCC).. Eighteen omega-6-derived oxylipins were quantified in serum samples of 34 patients with chronic hepatitis B, 46 patients with HBV-related liver cirrhosis, 38 patients with HBV-related HCC, and 50 healthy controls using liquid chromatography tandem mass spectrometry.. Seven oxylipins were found to be altered in patients with HBV-related liver diseases, including 9,10-dihydroxyoctadecenoic acid (9,10-DiHOME), 12,13-DiHOME, 14,15-dihydroxyeicosatrienoic acid (14,15-DiHETrE), 13-hydroxyoctadecadienoic acid (13-HODE), 12-hydroxyeicosatetraenoic acid (12-HETE), 11-HETE, and thromboxane B. This study for the first time shows the correlations between CYP450-derived oxylipins and the progression of chronic HBV infection, and sheds a new light on the surveillance of HBV-related live diseases using oxylipins.

    Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Linoleic Acids; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Oleic Acids; Oxylipins; Thromboxane B2

2018
Dietary fish oil deactivates a growth-promoting signaling pathway in hepatoma 7288CTC in Buffalo rats.
    Nutrition and cancer, 2006, Volume: 56, Issue:2

    Dietary fish oil decreases growth of solid tumors in rodents. Mechanisms for this effect are not well defined. In rat hepatoma 7288CTC, short-term (1-2 h) treatment with eicosapentaenoic acid during perfusion in situ reduced fatty acid uptake and [(3)H]thymidine incorporation. To determine if dietary fish oil had this effect in vivo, 48 male Buffalo rats were implanted with tissue-isolated hepatoma 7288CTC and were divided into three groups: Diet I (8% olive oil/2% corn oil), Diet II (6% olive oil/2% corn oil/2% fish oil), or Diet III (3% olive oil/3% corn oil/4% fish oil). When tumors weighed 4 to 6 g rats were anesthetized and tumor fatty acid uptake and 13-hydroxyoctadecadienoic acid release were measured in vivo by arterial minus venous differences. Tumors were analyzed for cyclic adenosine monophosphate (cAMP), DNA content, and [(3)H]thymidine incorporation. Fish oil feeding significantly (P < 0.05) reduced tumor growth, cAMP content, fatty acid uptake, 13-hydroxyoctadecadienoic acid formation, DNA content, and [(3)H]thymidine incorporation. Addition of either pertussis toxin or 8-bromoadenosine-cAMP to the arterial blood reversed the inhibitions in tumors in rats fed diet II. These results provide in vivo evidence that dietary fish oil suppressed a specific linoleic acid-dependent, inhibitory G protein-coupled, growth-promoting signaling pathway in rat hepatoma 7288CTC.

    Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cyclic AMP; Dietary Fats, Unsaturated; DNA, Neoplasm; Fish Oils; Linoleic Acids; Liver Neoplasms, Experimental; Male; Random Allocation; Rats; Rats, Inbred BUF; Rats, Sprague-Dawley; Signal Transduction

2006